Effects of bpV(pic) and bpV(phen) on H9c2 cardiomyoblasts during both             hypoxia/reoxygenation and H2O2-induced injuries.
Reactive oxygen species (ROS) are involved in myocardial injury. ROS are             known to inactivate lipid phosphatase and tension homolog on chromosome 10 (PTEN),             an enzyme that increases apoptosis in neonatal cardiomyocytes. BpV(pic) and bpV(phen),             two bisperoxovanadium molecules and PTEN inhibitors, may be involved in limiting             myocardial infarction. To compare the protective effects of bpV(pic) and bpV(phen)             on ROS-induced cardiomyocyte injury and their possible mechanisms, we selected             two popular models of hypoxia/reoxygenation (H/R) and H2O2-induced injury in H9c2             cardiomyoblasts to investigate their effects against injury. We found that pre-treatment             with bpV(pic) and bpV(phen) increased the viability and protected the morphology             of H9c2 cells under the conditions of H/R and H2O2 by inhibiting LDH release,             apoptosis and caspases 3/8/9 activities. However, their respective inhibitory             abilities in the two models were different, suggesting that the quantity of ROS             from the two models might be different. However, the conflict between ROS and             PTEN may affect the action of bpV(pic) and bpV(phen). Taken together, the results             demonstrate that bpV(pic) and bpV(phen) have inhibitory effects on oxidative stress-induced             cardiomyocyte injury that may be partially modulated by the action of ROS on PTEN.
New Drug Screening Center, China Pharmaceutical University, Nanjing, Jiangsu 210009, PR China.
Youqing
Y
Tian
Abdelkader
A
Daoud
Jing
J
Shang
D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D002316:Cardiotonic Agents / Q000494:pharmacology*; D020169:Caspases / Q000378:metabolism; D015687:Cell Hypoxia / Q000187:drug effects; D002460:Cell Line; D006861:Hydrogen Peroxide / Q000633:toxicity*; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D032383:Myocytes, Cardiac / Q000187:drug effects*; D009942:Organometallic Compounds / Q000737:chemistry / Q000494:pharmacology*; D051059:PTEN Phosphohydrolase / Q000037:antagonists & inhibitors / Q000378:metabolism; D010618:Phenanthrolines / Q000737:chemistry / Q000494:pharmacology*; D051381:Rats; D017968:Vanadium Compounds / Q000737:chemistry / Q000494:pharmacology*
D002316:Cardiotonic Agents; D009942:Organometallic Compounds; D010618:Phenanthrolines; D017968:Vanadium Compounds; C472777:bisperoxovanadium; C119540:oxodiperoxo(pyridine-2-carboxylate)vanadate(V); C102120:bisperoxo(1,10-phenanthroline)oxovanadate(1-); D006861:Hydrogen Peroxide; D007770:L-Lactate Dehydrogenase; D051059:PTEN Phosphohydrolase; D020169:Caspases